Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Legnano – page 138

2 907 clinical trials in Legnano, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Legnano at a glance
2 907
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 907 trials in Legnano

Open in trial search

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Acute myocardial infarction

Not recruiting

A study of ziltivekimab compared to placebo for reducing heart problems in patients who have had a heart attack

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Dermatitis atopic

Not recruiting

Study of Rocatinlimab with Topical Treatments for Adults with Moderate to Severe Atopic Dermatitis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Breast cancer+1

Not recruiting

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Non-small cell lung cancer

Not recruiting

Study of zoldonrasib in patients with RAS G12D mutation non-small cell lung cancer who have received previous treatment

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Revolution Medicines Inc.

Non-small cell lung cancer stage III

Not recruiting

Study of radiotherapy with durvalumab and ceralasertib in patients with stage III non-small cell lung cancer who have thoracic relapse after PACIFIC treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
  • Sponsor:Mario Negri Institute For Pharmacological Research

Retinitis pigmentosa

Not recruiting

Study of ultevursen treatment in patients with retinitis pigmentosa caused by mutations in USH2A gene exon 13

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ultevursen
  • Sponsor:Laboratoires Thea

Fabry's disease

Not recruiting

Study comparing venglustat tablets with standard therapy for adult patients with Fabry disease and left ventricular hypertrophy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Agalsidase beta
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Neoplasm

Not recruiting

Long-term study of dabrafenib and trametinib in children and adolescents with cancers that have V600 mutation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Dabrafenib Mesylate
  • Sponsor:Novartis Pharma AG

Endocrine ophthalmopathy

Not recruiting

Study of VRDN-001 compared to placebo to evaluate safety and effectiveness in adults with chronic thyroid eye disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Viridian Therapeutics Inc.

Duchenne muscular dystrophy

Not recruiting

Study of BMN 351 given by intravenous infusion to evaluate safety and tolerability in patients with Duchenne Muscular Dystrophy

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:BMN 351
  • Sponsor:Biomarin Pharmaceutical Inc.

Colitis ulcerative

Not recruiting

Study of efavaleukin alfa safety and effectiveness in adults with moderate to severe ulcerative colitis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Legnano

What the registry says about research in the country

01 Hematologic Oncology

Extensive research focusing on Multiple Myeloma treatments, including innovative therapies for relapsed and refractory cases. Studies evaluating new drug combinations and treatment approaches for better patient outcomes.

  • Melflufen therapy for elderly patients
  • Elranatamab monotherapy trials
  • Novel combination treatments for RRMM

Multiple ongoing trials testing various therapeutic combinations to improve survival rates.

02 Solid Tumors

Groundbreaking studies in lung cancer and breast cancer treatment, investigating novel immunotherapy combinations and targeted therapies.

  • Advanced NSCLC immunotherapy trials
  • HER2-positive breast cancer treatments
  • Colorectal cancer targeted therapies

Focus on personalized treatment approaches and biomarker-driven therapies.

03 Chronic Conditions

Innovative research in chronic kidney disease and HIV management, exploring new treatment strategies and medication combinations.

  • Non-diabetic kidney disease treatments
  • HIV antiretroviral therapy optimization
  • Ulcerative colitis interventions

Studies aimed at improving long-term patient outcomes and quality of life.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.